The amount of commercial milestone payments under the collaboration agreement.

No definition available.

Name:	elev_CollaborationAgreementCommercialMilestonePayments
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of development and regulatory milestone payments under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAgreementDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Term of the collaboration agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAgreementTerm
Namespace Prefix:	elev_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of upfront license fee payable under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAgreementUpfrontLicenseFee
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount payable as percentage of non royalty sublease income.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAgreementsPaymentsAsPercentageOfNonRoyaltySubleaseIncome
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number days of prior written notice to terminate the agreement.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsNoticePeriod
Namespace Prefix:	elev_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=elev_CSPCLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=elev_CspcMegalithBiopharmaceuticalCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=elev_SynaffixLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Asset Purchase and License Agreements - License Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jul. 31, 2022	Mar. 31, 2025	Mar. 31, 2024	Sep. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 6,876	$ 6,011
CSPC License Agreement \| CSPC Megalith Biopharmaceutical Co., Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee	$ 27,000
Term of agreement (in years)	10 years
Number of days written prior notice to terminate agreement	180 days
CSPC License Agreement \| CSPC Megalith Biopharmaceutical Co., Ltd \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and regulatory milestone payments	$ 148,000
Commercial milestone payments	1,000,000
Payments as percentage of non-royalty sublicense income	$ 50,000
Synaffix License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Commercial milestone payments				$ 365,500
Research and development		$ 0	$ 0